The present work provides corroborating evidence that DDX3 is required for cancer cell proliferation both in vitro and in vivo and targeting DDX3 with a small molecule inhibitor, NZ51, could be a viable option for breast cancer treatment. Here, DDX3X is linked to breast cancer.